Artivion (NYSE:AORT) Sets New 12-Month Low Following Analyst Downgrade

Key Points

• Artivion shares hit a new 52-week low after Citizens JMP cut its price target from $53 to $48, adding to a broader selloff that pushed the stock well below its prior close.
• Recent analyst actions have been mixed but generally still constructive: several firms maintained Buy ratings, though Needham and Citizens JMP lowered price targets, and Wall Street now shows a consensus “Moderate Buy” with a $47.83 target.
• Despite the stock weakness, Artivion’s latest quarter was solid, with revenue up 18% and adjusted EPS beating estimates; the company also received FDA approval for the NEXUS Aortic Arch System and exercised its option to acquire Endospan.

Artivion, Inc. (NYSE:AORT - Get Free Report) reached a new 52-week low on Saturday after Citizens Jmp lowered their price target on the stock from $53.00 to $48.00. Citizens Jmp currently has a market outperform rating on the stock. Artivion traded as low as $19.16 and last traded at $25.3640, with a volume of 5135733 shares traded. The stock had previously closed at $35.42.

AORT has been the subject of several other research reports. Wall Street Zen cut Artivion from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. Canaccord Genuity Group decreased their target price on shares of Artivion from $51.00 to $48.00 and set a "buy" rating on the stock in a research report on Friday, February 13th. Needham & Company LLC lowered their target price on shares of Artivion from $58.00 to $44.00 and set a "buy" rating for the company in a report on Friday. LADENBURG THALM/SH SH raised shares of Artivion from a "neutral" rating to a "buy" rating and set a $42.00 price target for the company in a research report on Friday, April 10th. Finally, Stifel Nicolaus set a $55.00 price target on shares of Artivion in a research note on Thursday, March 5th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $47.83.

Insider Buying and Selling at Artivion

In other Artivion news, insider John E. Davis sold 4,573 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $172,767.94. Following the completion of the sale, the insider directly owned 230,794 shares in the company, valued at $8,719,397.32. The trade was a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jean F. Holloway sold 8,962 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the sale, the senior vice president directly owned 185,095 shares of the company's stock, valued at $7,033,610. The trade was a 4.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 133,043 shares of company stock valued at $4,977,158. 6.30% of the stock is currently owned by corporate insiders.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Artivion reported Q1 2026 revenue of $116.3 million, up 18% year over year, and adjusted EPS of $0.08, topping analyst estimates. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Positive Sentiment: Adjusted EBITDA rose 26% to $22.1 million, showing improving profitability as the company grows. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Positive Sentiment: The FDA approved the NEXUS Aortic Arch System, a meaningful regulatory win that could expand Artivion’s addressable market and support future growth. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Positive Sentiment: Artivion exercised its option to acquire Endospan, which may strengthen its aortic disease portfolio over time. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Neutral Sentiment: The company guided 2026 revenue to $480 million-$496 million, which is near Wall Street expectations but not a major upside surprise. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
• Negative Sentiment: Despite the beat-and-raise style quarter, investors appear focused on the stock’s rich valuation and the lack of a major guidance surprise, contributing to the selloff. Why is Artivion stock plummeting today?
• Negative Sentiment: Citizens JMP and Needham both lowered price targets, which may have added to the negative sentiment even though both firms kept bullish ratings. Benzinga report on lowered price targets

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AORT. Vanguard Group Inc. boosted its position in shares of Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company's stock worth $144,588,000 after buying an additional 141,030 shares during the period. Morgan Stanley raised its holdings in shares of Artivion by 0.8% during the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company's stock valued at $102,930,000 after buying an additional 18,248 shares during the period. State Street Corp lifted its position in Artivion by 2.9% during the 4th quarter. State Street Corp now owns 1,584,920 shares of the company's stock worth $72,288,000 after acquiring an additional 44,641 shares in the last quarter. Fred Alger Management LLC lifted its position in Artivion by 4.2% during the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company's stock worth $62,603,000 after acquiring an additional 55,322 shares in the last quarter. Finally, Conestoga Capital Advisors LLC purchased a new position in Artivion in the 1st quarter worth approximately $43,044,000. Institutional investors and hedge funds own 86.37% of the company's stock.

Artivion Stock Performance

The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The stock has a fifty day simple moving average of $36.50 and a two-hundred day simple moving average of $41.19. The stock has a market cap of $1.23 billion, a PE ratio of 105.69 and a beta of 1.41.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. The company had revenue of $116.34 million for the quarter, compared to analyst estimates of $115.69 million. Artivion had a net margin of 2.55% and a return on equity of 7.21%. The business's quarterly revenue was up 17.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.01) earnings per share. Equities analysts anticipate that Artivion, Inc. will post 0.63 EPS for the current fiscal year.

Artivion Company Profile

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.